Texas A&M Clinical Trial for DCM in dogs – The REPAIR Study – Rapamycin TrEatment in Preclinical CAnine DIlated CaRdiomyopathy

Title: Rapamycin TrEatment in Preclinical CAnine DIlated CaRdiomyopathy
(The REPAIR Study)
Contact Person: tamucardiology@cvm.tamu.edu
Species: Canine
Inclusion Criteria and General Background Information: Dogs with a prior diagnosis of occult dilated cardiomyopathy (ODCM) and being treated with pimobendan may be eligible to undergo a number of screening tests to confirm their eligibility for enrollment.

Background: Dilated cardiomyopathy (DCM) is the second most common acquired cardiac disease in dogs. The preclinical phase of DCM, often referred to as occult DCM (ODCM), can last for approximately two to three years. Current optimal management of dogs with ODCM includes pimobendan and/or antiarrhythmic medication. Once dogs with ODCM progress to the clinical phase of the disease, dogs often experience congestive heart failure and have limited (less than one year) life spans with diminished quality of life. This study aims to investigate if a new treatment, rapamycin, can reduce heart size and improve function during the occult/preclinical stage of dilated cardiomyopathy (ODCM) in dogs already receiving pimobendan. Dogs that pass the echocardiographic and full screening tests are eligible to enroll in this 6-month study. Dogs must be at least three years of age to be enrolled.

Exclusion Criteria: Dogs will not be eligible for enrollment if:
• They have been diagnosed with other cardiac diseases (congenital or acquired).
• They have/had signs of congestive heart failure.
• They have atrial fibrillation.
• They have fainted in the last three months.
• They have undergone general anesthesia in the last 30 days.
• They are receiving diuretics.
Owner Commitments: • Owners must be able to make a trip to Texas A&M to participate in the study at the time of screening for enrollment, and again at two, four, and six months after enrollment.
• Owners must be able to answer questions regarding their dog’s health at each of the screening visits.
Financial Incentives: All enrolled dogs will have diagnostic tests required by the study including blood work (complete blood count, biochemistry panel), ECG/Holter, and an echocardiogram (a cardiac ultrasound) conducted at no cost to the owner. In addition, the study will provide pimobendan at no cost to the owner during the course of the study. A Holter monitor deposit fee is charged and refunded when the Holter is returned.

Rapamycin TrEatment in Preclinical CAnine DIlated CaRdiomyopathy (The REPAIR Study)

 

Share on facebook
Facebook
Share on google
Google+
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest